26 February 2026
Efferon®LPS is available in Costa Rica

¡Hola, Costa Rica! Efferon ya está aquí.
We are proud to announce that Efferon®LPS has received official authorization in Costa Rica, becoming the 41st country where next-generation extracorporeal therapy is available!
We are especially pleased to expand our collaboration with US Pharmacy Group, our trusted and highly respected partner across Latin America. With their extensive regional expertise, strong professional network, and deep understanding of local healthcare systems, we are confident that together we will successfully introduce this life-saving technology to healthcare professionals and patients throughout Costa Rica.
Efferon®LPS is a next-generation hemoadsorption device designed to remove both endotoxins and cytokines from the bloodstream. It has received EU approval for use in sepsis patients under the MDR.
More news
- Efferon®NEO Receives CE MDR Mark22 April 2026
- Efferon at ISICEM10 April 2026
- Efferon first distributors meeting08 April 2026
- Efferon is now available in Poland11 March 2026
- Efferon®LPS is now approved in Thailand18 February 2026
- Efferon LPS® incorporated into clinical guidelines of the German Society of Nephrology for therapeutic apheresis10 December 2025
- We’ll see each other in Greece25 November 2025
- Efferon therapies are now available in Armenia!05 November 2025
- Clinical data confirmed the effectiveness of Efferon NEO in children with sepsis30 October 2025
- Efferon LPS has been approved in the Kingdom of Saudi Arabia.18 October 2025
- Extracorporeal removal of antibiotic drugs during Efferon LPS hemoadsorption is predictable and manageable09 October 2025
- Efferon at the 6th Asia Pacific AKI CRRT Congress in Bangkok05 October 2025
- Win a New iPad! Join the Efferon LPS Photo Challenge on LinkedIn12 September 2025
- Efferon LPS hemoadsorption device has been granted regulatory approval in the United Kingdom and Croatia.23 July 2025
- Efferon LPS Now Available in Italy01 July 2025
- Applying Vicenza’s Lessons28 June 2025
- Efferon Expands Its Global Presence23 June 2025
- Efferon expands to new markets with Bertossi partnership06 June 2025
- Efferon LPS becomes available in Romania.25 May 2025
- New distribution agreements in European countries22 July 2024
- Efferon LPS receives CE mark under EU MDR29 April 2024
- Results of LASSO mRCT are published in Shock20 April 2023
- Efferon at LIVES 2022 in Paris03 November 2022
- Efferon has participated in MEDICA30 November 2021
- LASSO multicenter randomized trial launched29 April 2021